Dihydroergotamine Injection Drug Interactions
- Dhe-45
- Trudhesa
- Atzumi
- Brekiya
- Migranal
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
About Dihydroergotamine Injection
Dihydroergotamine is used to treat migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light) and cluster headaches (severe headaches usually on one side of the head or around one eye). Dihydroergotamine is in a class of medications called ergot alkaloids.
Read the full Dihydroergotamine Injection drug information pageQuick links
The Bottom Line on Dihydroergotamine Injection
Dihydroergotamine is used to stop migraine and cluster headaches, the severe, throbbing kind that can come with nausea and sensitivity to light and sound. It has more documented interactions than most medicines, and most of them are rated serious, with a good number of those in the most cautionary category.
Fluoxetine is the one to know first. Taken alongside it, the body can end up with more of the headache medicine than expected, which raises the risk of ergotism, a poisoning that brings nausea, vomiting and narrowed blood vessels that starve tissue of blood. Once a year, bring every bottle you have, supplements included, to a pharmacist for a full review.
From the HelloPharmacist Editorial Team Written with AI from this page's interaction records · How we build these pages · How we use AI · Our editorial policy
Check Dihydroergotamine Injection Against Another Drug or Supplement
Type a drug, a brand name or a supplement. We check it against every documented dihydroergotamine injection interaction, supplements and herbs included.
What Could Happen When Dihydroergotamine Injection Interacts
What the 157 documented dihydroergotamine injection interaction records say could happen, grouped by the problem each one names. Tap a bar to see those drugs.
This chart covers drug interactions only. Interactions with supplements and herbs are studied far less, so they are not counted here; they have their own pages on this site. One interaction can name more than one problem, so the numbers add up to more than 157.
Dihydroergotamine Injection Interactions by Severity
Contraindicated
- Dihydroergotamine Injection and Adagrasib Explained Brand name: Krazati Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details
- Dihydroergotamine Injection and Almotriptan Explained Brand name: Axert Increased risk of coronary artery vasospasm Details
- Dihydroergotamine Injection and Amprenavir Explained Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, peripheral vasospasm, and peripheral isc... Details
- Dihydroergotamine Injection and Atazanavir Explained Brand name: Reyataz An increased risk of peripheral vasospasm and ischemia of the extremities and other tissues Details
- Dihydroergotamine Injection and Boceprevir Explained Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details
- Dihydroergotamine Injection and Bromocriptine Explained Brand names: Cycloset, Parlodel An increased risk of ergotism Details
- Dihydroergotamine Injection and Ceritinib Explained Brand name: Zykadia Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details
- Dihydroergotamine Injection and Clarithromycin Explained Brand names: Biaxin Filmtab, Biaxin, Biaxin XL Filmtab Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity (ergotism) Details
- Dihydroergotamine Injection and Cobicistat Explained Brand name: Tybost An increased risk of acute ergot toxicity (peripheral vasospasm, ischemia of the extremities) Details
- Dihydroergotamine Injection and Darunavir Explained Brand name: Prezista An increased risk of acute ergot toxicity (peripheral vasospasm, ischemia of the extremities) Details
- Dihydroergotamine Injection and Delavirdine Explained Brand name: Rescriptor Increased dihydroergotamine exposure and an increased risk of ergot toxicity (vasospastic ischemia) Details
- Dihydroergotamine Injection and Dobutamine Explained Increased risk of elevation of blood pressure Details
- Dihydroergotamine Injection and Dopamine Explained Increased risk of elevation of blood pressure Details
- Dihydroergotamine Injection and Eletriptan Explained Brand names: Relpax, Eletriptan HBR Increased risk of prolonged vasospastic reactions Details
- Dihydroergotamine Injection and Ensitrelvir Explained Increased ergot derivatives exposure; an increased risk of ergot derivatives-related toxicity Details
- Dihydroergotamine Injection and Ephedrine Explained Brand names: Akovaz, Emerphed, Bronkaid Max Increased risk of elevation of blood pressure Details
- Dihydroergotamine Injection and Epinephrine Explained Brand names: Auvi-Q, Adrenalin, Symjepi Increased risk of elevation of blood pressure Details
- Dihydroergotamine Injection and Ergoloid Mesylates Explained Brand names: Alkergot, Circanol, Gerimal An increased risk of ergotism Details
- Dihydroergotamine Injection and Ergonovine Explained An increased risk of ergotism Details
- Dihydroergotamine Injection and Ergotamine Explained Brand name: Ergomar An increased risk of ergotism Details
Look Up Another Drug
Still Have Questions About Dihydroergotamine Injection?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
The References Behind Dihydroergotamine Injection’s Interactions
The 472 sources our dihydroergotamine injection interaction records cite: clinical studies, case reports and FDA prescribing information. Each pair's page lists the ones it rests on, numbered in its text, and a source link is one we checked against PubMed or Crossref. How we check them →
- Product Information: ATZUMI(R) nasal powder, dihydroergotamine nasal powder. Satsuma Pharmaceuticals (per Manufacturer), Durham, NC, 2025. DailyMed
- Product Information: BREKIYA(R) subcutaneous injection, dihydroergotamine mesylate subcutaneous injection. Amneal Pharmaceuticals (Per Manufacturer), Bridgewater, NJ, 2025. DailyMed
- Product Information: TRUDHESA(TM) nasal spray, dihydroergotamine mesylate nasal spray. Impel NeuroPharma Inc (per DailyMed), Seattle, WA, 2021. DailyMed
- Product Information: D.H.E. 45(R) intravenous, intramuscular, subcutaneous injection, dihydroergotamine mesylate intravenous, intramuscular, subcutaneous injection. Valeant Pharmaceuticals North America LLC (per DailyMed), Bridgewater, NJ, 2017.
- Product Information: Migranal(R) nasal spray, dihydroergotamine mesylate nasal spray. Valeant Pharmaceuticals North America LLC (per DailyMed), Bridgewater, NJ, 2017. DailyMed
- Becker WJ, Riess CM, & Hoag J: Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache 1996; 36:144-148. PubMed
- May A, Evers S, Goadsby PJ, et al: European Academy of Neurology guidelines on the treatment of cluster headache. Eur J Neurol 2023; 30(10):2955-2979. PubMed
- Silberstein SD, Schulman EA, & McFadden Hopkins M: Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990; 30:334-339. PubMed
- Maurer G & Frick W: Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 1984; 26:463-470. PubMed
- Kanto J, Allonen H, Koski K, et al: Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol 1981; 19:127-130.